Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston Mover

Vertex Pharmaceuticals Inc. fell the most in seven weeks after an analyst with Leerink Swann & Co. cut sales estimates for a hepatitis C pill made by the company that was approved by U.S. regulators last year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.